152 related articles for article (PubMed ID: 29688882)
1. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
3. A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 - 2018.
Moldaver DM; Hassan S; Seung SJ; Edwin J; Clouthier DL; Vera-Badillo FE
Urol Oncol; 2023 Mar; 41(3):146.e13-146.e22. PubMed ID: 36641303
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
5. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.
Dragomir A; Rocha J; Vanhuyse M; Cury FL; Kassouf W; Hu J; Aprikian AG
Curr Oncol; 2017 Aug; 24(4):240-248. PubMed ID: 28874892
[TBL] [Abstract][Full Text] [Related]
7. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs.
Ferretti S; Mercinelli C; Marandino L; Litterio G; Marchioni M; Schips L
Res Rep Urol; 2023; 15():243-259. PubMed ID: 37396015
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Anticancer Res; 2020 Jan; 40(1):335-339. PubMed ID: 31892584
[TBL] [Abstract][Full Text] [Related]
11. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
[TBL] [Abstract][Full Text] [Related]
12. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
[TBL] [Abstract][Full Text] [Related]
15. Contemporary agents in the management of metastatic castration-resistant prostate cancer.
Kapoor A; Wu C; Shayegan B; Rybak AP
Can Urol Assoc J; 2016; 10(11-12):E414-E423. PubMed ID: 28096932
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
17. How many physicians does Canada need to care for our aging population?
Roos NP; Bradley JE; Fransoo R; Shanahan M
CMAJ; 1998 May; 158(10):1275-84. PubMed ID: 9614820
[TBL] [Abstract][Full Text] [Related]
18. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
Rawson NS
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE).
Ko JJ; Mbuagbaw L; Tyldesley S; Lowther J; Sunderland K; Royer C; Faure M; MacPhail C; Faizi S; Cheung WY; Lee-Ying R
Can Urol Assoc J; 2024 Mar; ():. PubMed ID: 38466865
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.
Gartrell BA; Saad F
Ther Adv Urol; 2015 Aug; 7(4):194-202. PubMed ID: 26445599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
